A Study of LY2484595 in Japanese Subjects

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 5.4% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Minimum age: 20 (lowers risk) · Who can join
• Blinding: quadruple (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 7.5% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 570 (raises risk) · Sponsor's track record
• Number of arms: 6 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 69.9% (lowers risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: subjectssubjectchronicsyndromeventricular
  Phrases that lowered it: aminotransferaseulnldlare currentlyjapanese
• Maximum age: not given (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 198 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 17905 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin NCT01218204 · started 2010 · scored riskier than 17% of active trials completed
• A Study of LY3015014 in Participants With High Cholesterol NCT01890967 · started 2013 · scored riskier than 31% of active trials completed
• A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2) NCT03361501 · started 2018 · scored riskier than 43% of active trials completed
• A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1) NCT03398005 · started 2018 · scored riskier than 42% of active trials completed
• Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia NCT05889156 · started 2023 · scored riskier than 41% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.